LSTA
Lisata Therapeutics, Inc. (LSTA) Scenario Analysis Analysis (2026)
Overall Score
Financial Health
Strong liquidity with a current ratio of 3.69 and cash ratio of 3.50.
No debt on the balance sheet, with debt-to-equity and debt-to-assets both at 0.
Working capital remains positive at $8.0M, supporting near-term flexibility.
Profitability
TTM margins remain deeply negative, with EBIT margin at -160.71% and net profit margin at -146.21%.
Returns on capital are severely negative, including ROIC at -1.99% and ROE at -1.14%.
Gross margin is high at 95%, but operating expenses are overwhelming revenue generation.
Valuation
The company trades at a very high EV/Sales multiple of 47.65x, indicating a demanding valuation despite weak fundamentals.
Price-to-book is 1.84x, which is not extreme on an asset basis given the balance sheet.
Negative earnings and cash flow make earnings-based valuation metrics less meaningful.
Efficiency
Asset turnover is extremely low at 0.01, showing very limited revenue generation from the asset base.
Receivables turnover is only 0.5x and days sales outstanding is 730, indicating slow collections.
Cash conversion cycle is highly negative due to unusual payables dynamics, but operating efficiency remains poor overall.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

